Never Run Out Of Buyers To Sell To.

20/20 OptimEyes Technologies is a pre-Series A biotechnology company developing a proprietary Mucoadhesive NanoParticle (MNP) platform designed to extend drug residence time on mucosal surfaces and enable sustained local delivery of small-molecule therapeutics. The company’s strategy is focused on creating commercially meaningful differentiation for pharmaceutical assets where rapid mucosal clearance currently limits real-world performance. Rather than pursuing novel molecular discovery, OptimEyes targets the structural constraint in drug delivery of insufficient surface residence time and…
Annual Revenue$1M to $5M
Estimated OwnershipBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.